Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2012 Aug 14;107(6):956–960. doi: 10.1038/bjc.2012.353

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

I Witzel 1, S Loibl 2, G von Minckwitz 2, H Eidtmann 3, T Fehm 4, F Khandan 5, S Schmatloch 6, M Hauschild 7, J Bischoff 8, P A Fasching 9, C Mau 10, C Schem 3, B Rack 11, I Meinhold-Heerlein 12, C Liedtke 13, T Karn 14, J Huober 15, C zu Eulenburg 16, Y Issa-Nummer 2, M Untch 10, V Müller 1,*
PMCID: PMC3464767  PMID: 22892393

Abstract

Background:

We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.

Methods:

The neoadjuvant GeparQuinto trial compared trastuzumab vs lapatinib in addition to chemotherapy in HER2-positive primary breast cancer patients. The sHER2 levels were measured by enzyme-linked immunosorbant assay in 210 patients, of whom 109 (52%) patients received trastuzumab and 101 (48%) lapatinib at three different time points.

Results:

Twenty-two percent of patients had elevated baseline sHER2 levels (>15 ng ml−1). A decrease of sHER2 levels (>20%) in the trastuzumab and lapatinib-treated group during NT was seen in 44% and 24% of the patients, an increase of sHER2 levels (>20%) was seen in 6% and 41% of patients, respectively. Higher pre-chemotherapy sHER2 levels were associated with higher pathological complete remission (pCR) rates in the entire study cohort (OR 1.8, 95% CI 1.02–3.2, P=0.043). A decline of sHER2 levels (>20%) during NT was a predictor for pCR in the lapatinib-treated patient group (OR: 11.7, 95% CI 1.3–110, P=0.031).

Conclusion:

Results of this study demonstrate that sHER2 levels change differently during NT depending on the anti-HER2 treatment strategy. Elevated baseline sHER2 levels (>15 ng ml−1) and a decrease of sHER2 levels (>20%) early after therapy initiation are both relevant criteria to predict response to lapatinib-based treatment.

Keywords: breast cancer, neoadjuvant therapy, HER2, serum, trastuzumab, lapatinib

Neoadjuvant therapy (NT) strategies allow an early assessment of treatment effects in breast cancer patients without long follow-up as required in the adjuvant setting. This is an opportunity for translational research projects examining biomarkers that should improve the understanding of mechanisms underlying treatment response. In the phase III GeparQuinto trial, patients with a HER2-positive primary tumour were randomly assigned to receive either trastuzumab or lapatinib in addition to four cycles of epirubicin/cyclophosphamide followed by four cycles of docetaxel (von Minckwitz et al, 2011; Untch et al, 2012).

Trastuzumab, a monoclonal antibody directed against the extracellular domain of HER2, has become a standard treatment in HER2-positive breast cancer in the adjuvant and neoadjuvant setting, increasing the pathological complete remission (pCR) rate significantly to around 40% (Buzdar et al, 2005; Untch et al, 2010, 2011). Lapatinib, an inhibitor of the intracellular tyrosine kinases of HER1 and HER2, has shown efficacy in metastatic breast cancer and is currently examined in early breast cancer (MacFarlane and Gelmon, 2011; Baselga et al, 2012).

The extracellular domain of the HER2 protein can be cleaved from the surface by metalloproteases and detected in the peripheral blood as serum HER2 (sHER2) (Codony-Servat et al, 1999; Tse et al, 2011). It was reported that the remaining cleaved HER2 receptor is constitutively activated (Hudelist et al, 2003), suggesting that the presence of sHER2 also reflects a biological process leading to a more aggressive tumour behaviour (Molina et al, 2002). Elevated levels of sHER2 are observed in patients with primary or metastatic breast cancer (Mueller et al, 2004; Witzel et al, 2010). Trastuzumab inhibits shedding of HER2 (Molina et al, 2001). In contrast, lapatinib was reported to enhance shedding of HER2 with an elevation of sHER2 levels in vitro (Vazquez-Martin et al, 2011), indicating a different mechanism of action. This could potentially lead to different sHER2 levels in patients treated with trastuzumab or lapatinib. In the previous GeparQuattro trial, we could demonstrate that sHER2 levels were a predictor for pCR in trastuzumab-treated patients (Witzel et al, 2010). However, the role of sHER2 in lapatinib-treated patients is still unclear. Therefore, we examined sHER2 levels in the context of neoadjuvant lapatinib treatment in the GeparQuinto trial.

Material and methods

The clinical study GeparQuinto

A total of 620 patients were scheduled to receive four cycles of EC (epirubicin 90 mg m−2, cyclophosphamide 600 mg m−2, day 1, every 3 weeks) followed by four cycles of docetaxel (100 mg m−2, day 1, every 3 weeks). Patients were randomly assigned to receive trastuzumab 6 mg kg−1 intravenously, every 3 weeks, starting with a loading dose of 8 mg kg−1 intravenously on day 1 of the first EC cycle or lapatinib 1250 mg per day starting on day 1 of the first cycle of EC until day 21 of the fourth cycle of docetaxel concomitantly to all chemotherapy cycles. Patients completed 1 year of anti-HER2 treatment with trastuzumab post surgery in both treatment groups.

Inclusion criteria for the translational subprotocol and ethical considerations

Full blood samples were collected for patients eligible for the GeparQuinto study in the participating centres at three different time points: before initiation of NT, after four cycles of epirubicin and cyclophosphamide and prior to surgery (Figure 1). Samples were stored at −20 °C and shipped on dry ice. All the patients gave written informed consent to blood collection as part of the correlative science programme, before entering the GeparQuinto study. Participation in the clinical trial was still possible even if a patient did not agree to participate in the correlative science programme. Patients were not informed about the laboratory results because of their experimental character. The clinical study as well as the translational research project described here were approved by the competent ethics committees. The disposition of patients (CONSORT diagram) is shown in Supplementary Figure 1.

Figure 1.

Figure 1

Open in a new tab

Serum collection in the HER2-positive patient cohort in the GeparQuinto trial. Abbreviations: C=cyclophophamide; E=epirubicin; H=trastuzumab; L=lapatinib and T=docetaxel.

Interventions

Serum samples from patients in study centres having agreed to biomaterial collection were send to the central laboratory of the German Breast Group. Correct labelling was checked and 210 serum samples (109 of patients in the trastuzumab arm and 101 of patients in the lapatinib arm) were forwarded to the Department of Gynecology, University Medical Center Hamburg-Eppendorf. The sHER2 assay was performed blinded for the clinical results. Detailed patient characteristics are listed in Table 1. No relevant differences between the patient characteristics of the full study population and the analysed subgroup were observed (data not shown).

Table 1. Baseline characteristics before neoadjuvant therapy and tumour response of patients with HER2-positive tumours in the trastuzumab and lapatinib group.

  Trastuzumab
Lapatinib
Parameter No. % No. %
Tumour size
 T1 16 15.4 11 11.2
 T2 50 48.1 45 45.9
 T3 18 17.3 27 27.6
 T4a–c 7 6.7 4 4.1
 T4d 13 12.5 11 11.2
 Missing 6   3  
         
Grading
 G1 1 0.9 1 1.0
 G2 53 48.2 48 46.2
 G3 56 51.8 55 52.8
         
Hormone receptor status
 ER positive/PR positive 38 34.5 41 39.4
 ER positive/PR negative 50 45.5 46 44.2
 ER negative/PR positive 3 2.7 4 3.8
 ER negative/PR negative 19 17.3 13 12.5
         
Clinical nodal status
 Negative 33 35.5 33 34.0
 Positive 69 64.5 64 66.0
 Missing 2   4  
         
pCR
 Yes 40 36 25 24
 No 70 64 79 76
Open in a new tab

Abbreviations: ER=oestrogen receptor; pCR=pathological complete remission; PR=progesterone receptor.

Enzyme-linked immunosorbant assay (ELISA)

The sHER2 was quantified by a commercially available ELISA (Wilex Inc, Cambridge, MA, USA) as previously described (Mueller et al, 2004). The results were expressed in ng ml−1. Each sample, standard and control, was assayed in duplicate. Inter-assay and intra-assay coefficients of variation were <10%. A currently used cut-off in the metastatic setting and also recommended by the manufacturer of the assay is 15 ng ml−1 (Esteva et al, 2002; Lipton et al, 2002). Therefore, serum levels >15 ng ml−1 were regarded as elevated. As a decrease of sHER2 levels of >20% during NT revealed significant results in the preceding GeparQuattro trial, we used the same cut-off (20%) for this analysis. We defined an increase of 20% during NT as significant in concordance to previous reports in metastatic breast cancer (Lipton et al, 2011).

Statistical analysis

The statistical analysis was performed using PASW Statistics 19.0 software (IBM, Armonk, NY, USA). The sHER2 levels were logarithmised for the analysis. A more than 20% change in sHER2 during therapy was defined as a significant change (Ali et al, 2008). The sHER2 levels were plotted against clinicopathological parameters by analysis of variance. The following groups were compared: tumour size <5 cm (cT1+2) vs >5 cm (cT3+4); G1/G2 vs G3; node-positive vs node-negative tumours; oestrogen receptor (ER) positive vs ER negative, progesterone receptor (PR) positive vs PR negative; and trastuzumab- vs lapatinib-treated patient cohort. Pathological complete remission was defined as no microscopic evidence of invasive and non-invasive residual tumour in the breast and lymph nodes. The correlation between pCR and baseline variables was tested by logistic regression in the univariate and multivariate analysis. A two-tailed P-value <0.05 was considered as statistically significant. Each analysis was also done separately for the trastuzumab- and lapatinib-treated patients. The study was performed in accordance to the REMARK criteria published and discussed (McShane et al, 2005; Hayes et al, 2006). The end point for our analysis was the clinical end point of the study, the pCR as defined by the protocol, in correlation with absolute values and changes of sHER2 levels.

Results

A total of 210 patients were included in this analysis. There was no difference between trastuzumab- and lapatinib-treated patients regarding median age, tumour size, nodal status and grading. Only rate of pCR differed between trastuzumab- and lapatinib-treated patients (36% for trastuzumab vs 24% for lapatinib, Table 1).

Serum HER2 levels

In all, 22 (20%) patients treated with trastuzumab and 24 (23%) patients treated with lapatinib had elevated sHER2 levels >15 ng ml−1 before chemotherapy. The median sHER2 levels before treatment were 9.9 ng ml−1 in both treatment arms. The median sHER2 level did not change significantly during trastuzumab therapy (8.8 ng ml−1 after four cycles of NT, 8.6 ng ml−1 pre-surgery) but increased slightly during lapatinib treatment (11.7 ng ml−1 after four cycles of NT, 10.7 ng ml−1 pre-surgery). The sHER2 levels after four cycles of NT and pre-surgery were higher in the lapatinib than in the trastuzumab group (P<0.001).

Change of sHER2 levels during chemotherapy

The rate of patients with a decline of sHER2 levels (>20%) after the first four cycles of NT was higher in the trastuzumab-treated group than the lapatinib-treated group (P=0.001). A total of 48 (44%) trastuzumab-treated patients and 25 (24%) lapatinib-treated patients showed a decline of sHER2 levels (>20%) at this time point. A further decline of sHER2 levels between four cycles to pre-surgery was observed in 21 (19%) trastuzumab-treated patients and 29 (28%) lapatinib-treated patients (P=0.20).

An increase of sHER2 levels (>20%) during the first four cycles of chemotherapy was seen in 7 (6%) trastuzumab-treated patients, 43 (41%) lapatinib-treated patients (P<0.001) and between four cycles to pre-surgery in 15 (14%) and 9 (9%) patients, respectively, (P=0.28) (Figure 2).

Figure 2.

Figure 2

Open in a new tab

Box plot of sHER2 changes after four cycles of chemotherapy in trastuzumab- and lapatinib-treated patients. Patients in the trastuzumab group experienced mainly sHER2 decreases, whereas in the lapatinib group, a significant number of sHER2 increases was observed.

Correlation between sHER2 levels and clinicopathological parameters

Higher sHER2 levels before chemotherapy were correlated with negative ER status (P<0.001). A positive correlation was observed between sHER2 levels and positive nodal status (P<0.008) and larger tumour size (P<0.001).

No other correlations between clinicopathological parameters, including age, grading, histological type, PR status and pre-chemotherapy sHER2 levels or sHER2 levels after four and eight cycles of chemotherapy, were observed (Table 2).

Table 2. sHER2 levels at three different time points.

  sHER2 pre-chemotherapy
sHER2 after four cycles of chemotherapy
sHER2 before surgery
Baseline characteristics Mean (ng ml −1 ) P-value Mean (ng ml −1 ) P-value Mean (ng ml −1 ) P-value
T3/4 17.7 <0.001 10.8 n.s. 9.9 n.s.
T1/2 11.1   10.3   9.9  
G3 14.5 n.s. 10.8 n.s. 10.1 n.s.
G1/2 12.5   10.3   9.7  
cN1 14.9 0.008 10.6 n.s. 9.8 n.s.
cN0 10.3   10.3   10.0  
ER negative 15.6 <0.001 10.9 n.s. 9.8 n.s.
ER positive 11.6   10.2   9.9  
Open in a new tab

Abbreviations: ER=oestrogen receptor; n.s.=not significant.

Pathological complete remission in relation to sHER2 levels and clinicopathological parameters

Regarding the entire patient cohort, an association between pCR and negative hormone receptor status (P=0.01 for ER and P=0.032 for PR), higher pre-chemotherapy sHER2 levels (P=0.043) and a decline of sHER2 levels (>20%) after four cycles of chemotherapy (P=0.049) in univariate analysis were observed. We could demonstrate linearity between pre-chemotherapy sHER2 levels and the probability of a pCR, but could not define a specific cut-off level for sHER2 to predict pCR.

In the trastuzumab-treated patient cohort, a decrease of sHER2 levels (>20%) during NT (before therapy to after four cycles of chemotherapy) was associated with pCR in univariate analysis (P=0.046), which was not significant in multivariate analysis (OR: 2.76, 95% CI 0.91–8.35, P=0.07, Table 3) adjusted for pre-chemotherapy sHER levels, tumour size, nodal status, grading and ER status.

Table 3. Correlation of clinicopathological parameters with pCR in the trastuzumab-treated and lapatinib-treated patient group (multivariate analysis).

  Trastuzumab
Lapatinib
Baseline characteristics Odds ratio P-value Odds ratio P-value
T3/4 vs T1/2 2.1 0.15 0.71 0.59
G3 vs G1/2 1.9 0.18 1.22 0.73
cN0 vs cN1 2.2 0.12 3.78 0.033
HR positive vs HR negative 0.5 0.17 0.21 0.013
Pre-chemotherapy sHER2 levels 1.5 0.49 10.8 0.01
sHER2 decrease >20% vs sHER2 decrease ⩽ 20% 2.76 P=0.07 11.7 0.031
Open in a new tab

Abbreviations: HR=hormone receptor; pCR=pathological complete remission; sHER2=serum HER2.

In the lapatinib-treated patient cohort, negative ER status (P=0.025) was associated with pCR in univariate analysis. However, in the multivariate analysis, higher pre-chemotherapy sHER2 levels (OR: 10.7, 95% CI 1.7–65, P=0.01), as well as a decrease of sHER2 levels (>20%) after four cycles of NT (OR: 11.7, 95% CI 1.3–110, P=0.031), were associated with pCR. In addition, patients with negative ER status and positive nodal status showed higher pCR rates in multivariate analysis adjusted for tumour size and grading (Table 3). An increase of sHER2 levels during therapy (>20%) was not associated with pCR in both groups (data not shown).

Discussion

In this prospective evaluation of sHER2 levels in patients treated with either trastuzumab or lapatinib in the neoadjuvant GeparQuinto trial, we observed that a decrease of sHER2 levels during therapy was associated with pCR in the lapatinib-treated patient group. However, sHER2 levels increased more frequently during lapatinib compared with trastuzumab treatment.

To the best of our knowledge, this is the first study on sHER2 levels in patients treated with lapatinib in the neoadjuvant setting. In the previous GeparQuattro trial applying only trastuzumab for HER2-positive patients, we observed that elevated sHER2 levels before and a decrease of >20% during NT (measured before and after NT) were associated with pCR (Witzel et al, 2010). In the current GeparQuinto trial comparing the two different anti-HER2 treatment strategies trastuzumab and lapatinib, we found also in lapatinib-treated patients that sHER2 levels are a potential predictor of pCR in addition to their effect in trastuzumab-treated patients.

Recently, results of large NT trials comparing different HER2-targeted therapy strategies were published (Baselga et al, 2012; Gianni et al, 2012). However, predictive markers to choose between different therapeutic options and a profound understanding of the mechanisms underlying the action of these approaches are missing.

The biological relevance of elevated sHER2 is still unknown. Some studies have suggested a better response to trastuzumab in patients with HER2-positive tumours and elevated sHER2 levels (Köstler et al, 2004; Witzel et al, 2010), whereas other studies have reported limited predictive utility for sHER2 (Mazouni et al, 2007). High sHER2 levels might also indicate increased HER2 cleavage and shedding. An activation of the signalling kinase domain through HER2 shedding could be mediated via truncated cell-associated fragments of HER2 and a consecutively deregulated growth-promoting pathway (Baselga, 2001). This hypothesis is based on the increased signalling of the p95 subunit of HER2 in cleaved HER2 receptors. The p95 protein is the intracellular component of HER2 that remains after shedding of the extracellular domain and contains the kinase domain. Some studies suggested that HER2 cleavage and subsequent activation of the p95 subunit is blocked by trastuzumab (Molina et al, 2001) but increased tumour p95 content has also been put forward as an escape mechanism mediating trastuzumab resistance and lapatinib sensitivity (Scaltriti et al, 2007). Therefore, it was hypothesised that the truncated HER2 receptor might not be ideally treated with trastuzumab but rather with agents targeting the intracellular region of the receptor like the tyrosine kinase inhibitor lapatinib (Vazquez-Martin et al, 2011). Although the analysis presented here did not directly measure tumour p95 content or its kinase activity, we can conclude that elevated sHER2 levels have an independent predictive impact on the response to HER2 kinase targeting therapy with lapatinib in the neoadjuvant setting. The effect of combined treatment of lapatinib and trastuzumab on receptor shedding is not clear so far because the GeparQuinto trial did not combine lapatinib and trastuzumab treatment, like for example, the NeoAltto Trial (Baselga et al, 2012).

The pCR rates in our group of patients were lower in the lapatinib group (26% vs 36% in the trastuzumab group), but the association of sHER2 with treatment response was more prominent with lapatinib. A decline of sHER2 levels during therapy, as well as sHER2 elevation before therapy, was an independent predictor of pCR in the lapatinib-treated patient group in multivariate analysis. In line with lapatinib treatment in the metastatic setting (Lipton et al, 2011), we could demonstrate that a decline of sHER2 levels early after the start of chemotherapy is relevant.

In our study, an increase of sHER2 levels during NT (>20%) was seen more often in the lapatinib group (41% vs 6% in the trastuzumab group). This is in line with published data from cell culture experiments showing that sHER2 levels are higher in the presence of lapatinib compared with trastuzumab (Vazquez-Martin et al, 2011). In the EGF30001 study, metastatic breast cancer patients with a conversion of sHER2 levels from high to low during treatment with lapatinib or placebo plus paclitaxel had a longer progression-free survival than patients with a conversion from low to high during therapy (Finn et al, 2009). In the EGF 20009 study, a decrease of sHER2 levels during the first 16 weeks of lapatinib monotherapy in patients with metastatic breast cancer was associated with better clinical outcome (increased response rate and longer progression-free interval), whereas an increase of >20% was associated with worse clinical outcome (Lipton et al, 2011). We could not demonstrate an association of increasing sHER2 levels with lower pCR rates in the lapatinib-treated patient group. Although we were able to show linearity between sHER2 levels and pCR, we could not define a cut-off level for sHER2 levels with an optimum in predicting pCR rates.

In conclusion, this is the first analysis of sHER in the context of lapatinib treatment in the neoadjuvant setting. Our findings support preclinical models indicating different effects of trastuzumab and lapatinib on HER2 receptor shedding. They suggest that elevated baseline sHER2 levels (>15 ng ml−1) and a decrease of sHER2 levels (>20%) early after therapy initiation have the potential to predict response to lapatinib treatment.

Acknowledgments

We thank Maila Rossberg and Kati Beck for their excellent technical assistance and the staff of the German Breast Group for their support in this translational research project. Most of all, we thank the patients of the clinical trial GeparQuinto who participated in this substudy.

Footnotes

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Part of this work was presented at the San Antonio Breast Cancer Conference in San Antonio, TX, USA in December 2011.

Advisory role/remuneration: Gunter von Minckwitz (Roche), Holger Eidtmann (Roche), Tanja Fehm (Roche), Joachim Bischoff (Roche), Peter Fasching (Novartis), Brigitte Rack (Roche, Novartis and GlaxoSmithKline), Jens Huober (Roche and GlaxoSmithKline) and Volkmar Müller (Amgen, Celgene, Sanofi-Aventis, Pierre-Fabre and Roche). Honoraria: Gunter von Minckwitz (Roche) and Peter Fasching (Novartis). Research funding: Gunter von Minckwitz (GlaxoSmithKline and Roche), Tanja Fehm (Roche, Novartis and GlaxoSmithKline), Joachim Bischoff (GlaxoSmithKline), Peter Fasching (Novartis), Jens Huober (GlaxoSmithKline) and Volkmar Müller (Roche). The remaining authors declare no conflict of interest.

Supplementary Material

Supplementary Figure 1
Click here for additional data file. (101.5KB, ppt)
Supplementary Figure Legend
Click here for additional data file. (21.5KB, doc)

References

  1. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Kostler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A (2008) Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113: 1294–1301 [DOI] [PubMed] [Google Scholar]
  2. Baselga J (2001) Is circulating HER-2 more than just a tumor marker? Clin Cancer Res 7: 2605–2607 [PubMed] [Google Scholar]
  3. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379: 596–598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685 [DOI] [PubMed] [Google Scholar]
  5. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59: 1196–1201 [PubMed] [Google Scholar]
  6. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808 [DOI] [PubMed] [Google Scholar]
  7. Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M (2009) Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 27: 5552–5558 [DOI] [PubMed] [Google Scholar]
  8. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25–32 [DOI] [PubMed] [Google Scholar]
  9. Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100: 237–238 [DOI] [PubMed] [Google Scholar]
  10. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF (2003) Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983–991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Köstler WJ, Steger GG, Soleiman A, Schwab B, Singer CF, Tomek S, Brodowicz T, Krainer M, Wiltschke C, Horvat R, Jakesz R, Zielinski CC (2004) Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 24: 1127–1130 [PubMed] [Google Scholar]
  12. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J (2002) Elevated serum her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467–1472 [DOI] [PubMed] [Google Scholar]
  13. Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J (2011) Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer 117: 5013–5020 [DOI] [PubMed] [Google Scholar]
  14. MacFarlane RJ, Gelmon KA (2011) Lapatinib for breast cancer: a review of the current literature. Expert Opin Drug Saf 10: 109–121 [DOI] [PubMed] [Google Scholar]
  15. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M (2007) Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109: 496–501 [DOI] [PubMed] [Google Scholar]
  16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180–1184 [DOI] [PubMed] [Google Scholar]
  17. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744–4749 [PubMed] [Google Scholar]
  18. Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J, Baselga J, Clinton GM (2002) NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347–353 [PubMed] [Google Scholar]
  19. Mueller V, Witzel I, Luck HJ, Kohler G, von Minckwitz G, Mobus V, Sattler D, Wilczak W, Loning T, Jaenicke F, Pantel K, Thomssen C (2004) Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86: 9–18 [DOI] [PubMed] [Google Scholar]
  20. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon Y, Cajal S, Arribas J, Baselga J (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628–638 [DOI] [PubMed] [Google Scholar]
  21. Tse C, Gauchez AS, Jacot W, Lamy PJ (2011) HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev 38: 133–142 [DOI] [PubMed] [Google Scholar]
  22. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29: 3351–3357 [DOI] [PubMed] [Google Scholar]
  23. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kuhn T, Nekljudova V, von Minckwitz G (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13: 135–144 [DOI] [PubMed] [Google Scholar]
  24. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol 28: 2024–2031 [DOI] [PubMed] [Google Scholar]
  25. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA (2011) Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol 226: 52–57 [DOI] [PubMed] [Google Scholar]
  26. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M (2011) Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 22: 301–306 [DOI] [PubMed] [Google Scholar]
  27. Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Muller V (2010) Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 123: 437–445 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1
Click here for additional data file. (101.5KB, ppt)
Supplementary Figure Legend
Click here for additional data file. (21.5KB, doc)

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES